AU2016289454B2 - Diaryl macrocycle polymorph - Google Patents

Diaryl macrocycle polymorph Download PDF

Info

Publication number
AU2016289454B2
AU2016289454B2 AU2016289454A AU2016289454A AU2016289454B2 AU 2016289454 B2 AU2016289454 B2 AU 2016289454B2 AU 2016289454 A AU2016289454 A AU 2016289454A AU 2016289454 A AU2016289454 A AU 2016289454A AU 2016289454 B2 AU2016289454 B2 AU 2016289454B2
Authority
AU
Australia
Prior art keywords
compound
formula
alkyl
boc
trifluoroacetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016289454A
Other languages
English (en)
Other versions
AU2016289454A1 (en
Inventor
Jingrong J. Cui
Evan W. ROGERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turning Point Therapeutics Inc
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of AU2016289454A1 publication Critical patent/AU2016289454A1/en
Assigned to Turning Point Therapeutics, Inc. reassignment Turning Point Therapeutics, Inc. Amend patent request/document other than specification (104) Assignors: TP THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2016289454B2 publication Critical patent/AU2016289454B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
AU2016289454A 2015-07-06 2016-07-05 Diaryl macrocycle polymorph Active AU2016289454B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562188846P 2015-07-06 2015-07-06
US62/188,846 2015-07-06
US201562218672P 2015-09-15 2015-09-15
US62/218,672 2015-09-15
PCT/US2016/040972 WO2017007759A1 (en) 2015-07-06 2016-07-05 Diaryl macrocycle polymorph

Publications (2)

Publication Number Publication Date
AU2016289454A1 AU2016289454A1 (en) 2018-01-04
AU2016289454B2 true AU2016289454B2 (en) 2020-07-09

Family

ID=57685592

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016289454A Active AU2016289454B2 (en) 2015-07-06 2016-07-05 Diaryl macrocycle polymorph

Country Status (24)

Country Link
US (5) US10294242B2 (enExample)
EP (2) EP3319969B1 (enExample)
JP (2) JP6917974B2 (enExample)
KR (1) KR102623734B1 (enExample)
CN (2) CN113354653B (enExample)
AU (1) AU2016289454B2 (enExample)
BR (1) BR112018000297A2 (enExample)
CA (1) CA2990020C (enExample)
DK (1) DK3319969T3 (enExample)
ES (1) ES2979111T3 (enExample)
FI (1) FI3319969T3 (enExample)
HR (1) HRP20240780T1 (enExample)
HU (1) HUE067352T2 (enExample)
IL (2) IL256443B (enExample)
LT (1) LT3319969T (enExample)
MX (2) MX386680B (enExample)
PL (1) PL3319969T3 (enExample)
PT (1) PT3319969T (enExample)
RS (1) RS65593B1 (enExample)
RU (1) RU2765181C2 (enExample)
SI (1) SI3319969T1 (enExample)
SM (1) SMT202400213T1 (enExample)
WO (1) WO2017007759A1 (enExample)
ZA (1) ZA201708436B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3636649T (pt) 2014-01-24 2024-04-09 Turning Point Therapeutics Inc Diaril macrociclos como moduladores das proteínas quinases
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
FI3319969T3 (fi) * 2015-07-06 2024-06-13 Turning Point Therapeutics Inc Diaryylimakrosyklipolymorfi
RS66238B1 (sr) * 2015-07-21 2024-12-31 Turning Point Therapeutics Inc Hiralni diaril makrocikl i njegova primena u lečenju karcinoma
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技（苏州）有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
HRP20221502T1 (hr) 2017-12-19 2023-03-31 Turning Point Therapeutics, Inc. Makrociklički spojevi za liječenje bolesti
CN113956269A (zh) * 2018-04-16 2022-01-21 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的二(杂)芳基大环化合物
SG11202104017VA (en) 2018-10-22 2021-05-28 Esker Therapeutics Inc Tyk2 inhibitors and uses thereof
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
US20220411439A1 (en) * 2019-06-19 2022-12-29 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
IL293208A (en) * 2019-11-27 2022-07-01 Turning Point Therapeutics Inc Combination therapy involving diaryl macrocyclic compounds
CA3162632A1 (en) * 2019-11-27 2021-06-03 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
MX2022010945A (es) * 2020-03-02 2022-10-07 Turning Point Therapeutics Inc Usos terapeuticos de compuestos macrociclicos.
KR20230008767A (ko) * 2020-05-08 2023-01-16 산동 수안주 파마 코포레이션 리미티드 거대고리형 티로신 키나제 억제제의 결정형 및 그의 제조 방법
CN112174982A (zh) * 2020-09-10 2021-01-05 上海希迈医药科技有限公司 一种洛普替尼晶型及其制备方法
WO2025217347A2 (en) 2024-04-11 2025-10-16 Bristol-Myers Squibb Company Process of preparing repotrectinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203776A1 (en) * 2010-05-20 2013-08-08 Steven Wade Andrews Macrocyclic compounds as trk kinase inhibitors
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
ES2021105B3 (es) 1987-03-07 1991-10-16 Bayer Ag Procedimiento para la obtencion de 5-amino-4,6-dihalogeno piridinas.
AU679053B2 (en) 1993-03-25 1997-06-19 Pharmacia & Upjohn Company Indoletetralins having dopaminergic activity
KR100340159B1 (ko) 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
GB9403639D0 (en) * 1994-02-25 1994-04-13 Boots Co Plc Therapeutic agents
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
KR100539139B1 (ko) 2000-07-31 2005-12-26 에프. 호프만-라 로슈 아게 피페라진 유도체
AU2002227371B2 (en) 2000-12-08 2007-05-10 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
AU2002254114A1 (en) 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
AU2002322802A1 (en) * 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US8005919B2 (en) 2002-11-18 2011-08-23 Aol Inc. Host-based intelligent results related to a character stream
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
UA91698C2 (ru) * 2005-01-10 2010-08-25 Арена Фармасьютікалз, Інк. Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшенных увеличением уровня glp-1 крови
US8960547B2 (en) 2007-09-19 2015-02-24 E-Seek, Inc. Document scanner with instant retrieval process
US8270176B2 (en) 2008-08-08 2012-09-18 Stats Chippac Ltd. Exposed interconnect for a package on package system
TWM352384U (en) 2008-08-22 2009-03-11 Luff Technology Co Ltd Wireless detection device for club and system thereof
CA2735420C (en) 2008-09-08 2016-06-28 Merck Patent Gmbh Macrocyclic pyrimidines as protein kinase inhibitors
CN102224153B (zh) 2008-09-22 2014-04-30 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物
PL3372605T3 (pl) 2008-10-22 2022-03-07 Array Biopharma Inc. Podstawione związki pirazolo[1,5-a]pirymidynowe jako inhibitory kinaz trk
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
US9073926B2 (en) 2009-12-07 2015-07-07 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
WO2011071716A1 (en) 2009-12-07 2011-06-16 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
GB2482674B (en) 2010-08-09 2012-08-22 Rolls Royce Plc An aerofoil, an aerofoil sub-assembly and a method of making the same
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
EP2541470B1 (en) 2011-06-29 2017-10-04 Denso Wave Incorporated Information code and information code reader
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003802A2 (pt) * 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
WO2013045702A2 (en) 2011-09-29 2013-04-04 L'oreal Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
WO2013045701A2 (en) 2011-09-29 2013-04-04 L'oreal Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
WO2013045653A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors
BR112014009531A8 (pt) 2011-10-20 2018-01-16 Glaxosmithkline Llc aza-heterociclos bicíclicos substituídos e análogos como moduladores de sirtuína
PE20142339A1 (es) 2012-03-06 2015-01-15 Pfizer Derivados macrociclicos para el tratamiento de enfermedades
SG11201405563VA (en) 2012-03-09 2014-10-30 Lexicon Pharmaceuticals Inc Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
PL2834243T3 (pl) 2012-03-09 2018-09-28 Lexicon Pharmaceuticals, Inc. Związki na bazie pirazolo[1,5-a]pirymidyny, zawierające je kompozycje i sposoby ich zastosowania
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
ES2634014T3 (es) 2013-01-30 2017-09-26 Bayer Pharma Aktiengesellschaft Isotiazoles sustituidos con amino
CN105358534A (zh) 2013-04-23 2016-02-24 斯洛文尼亚莱柯制药股份有限公司 8-氯-1-甲基-苯并[d]吖庚因的新合成方法、新的中间体及其生产方法
WO2015012328A1 (ja) 2013-07-24 2015-01-29 武田薬品工業株式会社 複素環化合物
US10497029B2 (en) * 2013-10-21 2019-12-03 Disney Enterprises, Inc. Systems and methods for facilitating brand integration within online content and promoting that online content
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
BR202014004079U2 (pt) 2014-02-21 2015-10-27 Mix For You Ltda higienizador íntimo
WO2016070241A1 (en) 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
KR102659741B1 (ko) 2014-12-15 2024-04-23 주식회사 씨엠지제약 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도
WO2016133838A1 (en) 2015-02-20 2016-08-25 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
EP3246346B1 (en) 2015-03-09 2020-01-01 Sumitomo Rubber Industries, Ltd. Tire
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
WO2016144844A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Carboxamide inhibitors of irak4 activity
MA42038A (fr) 2015-05-05 2018-03-14 Bayer Pharma AG Dérivés de cyclohexane à substitution amido
RU2732405C2 (ru) * 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
US9524416B1 (en) 2015-07-03 2016-12-20 Fingerprint Cards Ab Fingerprint sensing device comprising three-dimensional pattern
FI3319969T3 (fi) * 2015-07-06 2024-06-13 Turning Point Therapeutics Inc Diaryylimakrosyklipolymorfi
US10239565B2 (en) 2015-07-17 2019-03-26 John Michael Baker Pickup truck tailgate lifting apparatus
RS66238B1 (sr) * 2015-07-21 2024-12-31 Turning Point Therapeutics Inc Hiralni diaril makrocikl i njegova primena u lečenju karcinoma
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法
JP6580495B2 (ja) 2016-02-02 2019-09-25 三菱重工業株式会社 保持治具
CN109153643B (zh) 2016-03-04 2022-06-21 范德比尔特大学 取代的吲哚mcl-1抑制剂
US10632076B2 (en) 2016-11-18 2020-04-28 Fertin Pharma A/S Tablet comprising separate binder and erythritol
EP3555137A1 (en) 2016-12-14 2019-10-23 Development Center for Biotechnology Antibody-drug conjugates and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203776A1 (en) * 2010-05-20 2013-08-08 Steven Wade Andrews Macrocyclic compounds as trk kinase inhibitors
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases

Also Published As

Publication number Publication date
RU2018104269A3 (enExample) 2019-12-17
US12187739B2 (en) 2025-01-07
ZA201708436B (en) 2021-03-31
IL256443B (en) 2021-05-31
WO2017007759A1 (en) 2017-01-12
JP2021119151A (ja) 2021-08-12
IL283184A (en) 2021-06-30
KR20180026480A (ko) 2018-03-12
DK3319969T3 (da) 2024-07-08
IL283184B2 (en) 2023-06-01
LT3319969T (lt) 2024-06-10
AU2016289454A1 (en) 2018-01-04
MX386680B (es) 2025-03-19
ES2979111T3 (es) 2024-09-24
EP3319969A4 (en) 2019-07-03
US20230295184A1 (en) 2023-09-21
JP2018529633A (ja) 2018-10-11
EP3319969B1 (en) 2024-04-03
CA2990020A1 (en) 2017-01-12
SI3319969T1 (sl) 2024-09-30
MX2021008145A (es) 2021-08-11
RU2018104269A (ru) 2019-08-06
PL3319969T3 (pl) 2024-06-24
US10294242B2 (en) 2019-05-21
PT3319969T (pt) 2024-06-17
CN113354653A (zh) 2021-09-07
BR112018000297A2 (pt) 2018-09-04
KR102623734B1 (ko) 2024-01-10
US20190233437A1 (en) 2019-08-01
US20250223298A1 (en) 2025-07-10
US20180194777A1 (en) 2018-07-12
HK1254492A1 (zh) 2019-07-19
HRP20240780T1 (hr) 2024-09-13
EP3319969A1 (en) 2018-05-16
HUE067352T2 (hu) 2024-10-28
RU2765181C2 (ru) 2022-01-26
RS65593B1 (sr) 2024-06-28
JP7212713B2 (ja) 2023-01-25
JP6917974B2 (ja) 2021-08-11
EP4397665A3 (en) 2024-08-21
EP4397665A2 (en) 2024-07-10
IL256443A (en) 2018-02-28
SMT202400213T1 (it) 2024-07-09
MX2017017081A (es) 2018-08-16
FI3319969T3 (fi) 2024-06-13
NZ738180A (en) 2024-04-26
CA2990020C (en) 2024-02-27
CN108026108A (zh) 2018-05-11
CN108026108B (zh) 2021-06-22
US20210094974A1 (en) 2021-04-01
CN113354653B (zh) 2024-12-31

Similar Documents

Publication Publication Date Title
AU2016289454B2 (en) Diaryl macrocycle polymorph
US20210032203A1 (en) Salts of an lsd1 inhibitor
US10300058B2 (en) Tyrosine kinase inhibitor and uses thereof
WO2023173017A1 (en) Kras inhibitors for treating disease
AU2022409472A1 (en) Macrocyclic btk inhibitors
WO2022246092A1 (en) Macrocyclic compounds for treating disease
US20220411439A1 (en) Polymorphs of a macrocyclic kinase inhibitor
HK40059224A (en) Diaryl macrocycle polymorph and method for preparing the same
HK1254492B (zh) 二芳基大环多晶型物
CN116589464A (zh) 嘧啶并环类化合物、其制备方法和应用

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: TURNING POINT THERAPEUTICS, INC.

Free format text: FORMER NAME(S): TP THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)